Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

NCT06936488 is registered in ClinicalTrials.gov with Huai'an First People's Hospital as lead sponsor.

NCT NCT06936488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06936488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
Lead sponsor
Huai'an First People's Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
March 1, 2025
Completion date
December 31, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mss/pmmr type metastatic colorectal adenocarcinoma patients